Search

Graphical AbstractAge-adjusted predictors of clinical outcomes in the ETNA-AF-Europe Registry.

We aimed to assess the safety of edoxaban in combination with P2Y12 inhibition in patients with atrial fibrillation who had percutaneous coronary intervention (PCI).

ABSTRACTMany countries in the Global South import a significant share of the food served to tourists. For decades, closer linkages of local food producer and the resort industry have been heralded as an antidote to this unsustainable circumstance, further encouraged by the current consumer trend around local food. Reflections on two qualitative research projects in resorts in South Africa and Fiji challenge the notion that tourists move out of their comfort zone to eat local dishes to any greater extent. Large-scale, internationally branded and managed resorts serve predominantly what their tourists from the Global North like to eat: a Western cuisine. If farmers want to benefit from this resort industry, they have to grow food according to the Western palate, which in turn has questionable impacts on biodiversity levels and environmental health in general. The discussion around localising tourism-related food chains in countries of the Global South needs to acknowledge for whose agenda food is being produced. “Corporate resorts” endorse neither a very sustainable nor a locally adaptable culinary agenda.

The prevalence of isolated systolic hypertension (ISH) is high in the elderly, and the objective of this study was to compare the antihypertensive efficacy of olmesartan medoxomil with that of nitrendipine in elderly (65–74 years) and very elderly (≥ 75 years) male and female patients with ISH.

To test whether adding hydrochlorothiazide (HCTZ) (12.5 or 25 mg) to olmesartan 20 mg improves 24-h blood pressure in patients whose conventional diastolic blood pressure is inadequately controlled by olmesartan monotherapy.

Orally administered olmesartan medoxomil was rapidly absorbed from the gastrointestinal tract and converted during absorption to olmesartan, the pharmacologically active metabolite that was subsequently excreted without further metabolism. The medoxomil moiety was released as diacetyl that was rapidly cleared by further metabolism and excretion. Peak plasma concentrations of olmesartan occurred 1–3 h after administration, after which concentrations decreased quickly. The elimination halflife was 10–15 h. Olmesartan medoxomil was not measurable in plasma and excreta. The volume of distribution was low, consistent with limited extravascular tissue distribution.

To assess the efficacy and safety of the novel angiotensin II antagonist olmesartan medoxomil in patients with mild to moderate essential hypertension, using a metaanalysis of the combined database from seven US and European clinical trials.

This study was conducted to assess the dose-response relationship of the new angiotensin II (Ang II) antagonist CS-866 on blood pressure and on endocrine parameters in hypertensive patients with an activated renin–angiotensin system.

Olmesartan medoxomil was rapidly absorbed and converted to olmesartan in elderly hypertensive patients, and in patients with renal and hepatic dysfunction. No olmesartan medoxomil itself was detected in plasma. Pharmacokinetic steady state was reached within the first few days after oral dosing.